IP
RDHL

Intellectus Partners’s Redhill Biopharma RDHL Stock Holding History

Intellectus Partners’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed -$9K – 448
2018
Q3 		$9K Hold
1
– – ﹤0.01% 485
2018
Q2 		$9K Buy
+1
New +$6.36K ﹤0.01% 484

Other funds holding RDHL

6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

Intellectus Partners's RDHL Position: Q4 2018 in Review

Intellectus Partners sold out of Redhill Biopharma (RDHL) in Q4 2018, closing a stake of 1 share — an estimated $9K sold.

Intellectus Partners first reported a position in RDHL in Q2 2018 and held it in 2 quarters. The position peaked at $9K in Q3 2018. 36 funds tracked by Wall St. Rank hold RDHL as of Q4 2018.

  • Intellectus Partners reported no remaining Redhill Biopharma position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 1 Redhill Biopharma share in Q4 2018, an estimated $9K.
  • Intellectus Partners first reported a position in Redhill Biopharma in Q2 2018 and held it in 2 quarters.
  • Intellectus Partners's Redhill Biopharma position peaked at $9K in Q3 2018.
  • 36 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.